Department of Biomedical and Organic Chemistry, Laboratoire National de Métrologie et d'Essais (LNE), 75724 Paris, France.
Biological Mass Spectrometry and Proteomics, SMBP, PDC UMR 8249 CNRS, ESPCI Paris, Université PSL, 75005 Paris, France.
Anal Chem. 2022 Mar 15;94(10):4146-4154. doi: 10.1021/acs.analchem.1c03061. Epub 2022 Mar 2.
Procalcitonin (PCT) is a widely used biomarker for rapid sepsis diagnosis and antibiotic stewardship. Variability of results in commercial assays has highlighted the need for standardization of PCT measurements. An antibody-free candidate reference measurement procedure (RMP) based on the isotope dilution mass spectrometry and protein calibration approach was developed and validated to quantify PCT in human serum. The method allows quantification of PCT from 0.25 to 13.74 μg/L ( > 0.998) with extension up to 132 μg/L after dilution of samples with PCT concentration above 13.74 μg/L. Intraday bias was between -3.3 and +5.7%, and interday bias was between -3.0 and -0.7%. Intraday precision was below 5.1%, and interday precision was below 4.0%. The candidate RMP was successfully applied to the absolute quantification of PCT in five frozen human serum pools. A recombinant PCT used as a primary calibrator was characterized by high-resolution mass spectrometry and amino acid analysis to establish traceability of the results to the SI units. This candidate RMP is fit to assign target values to secondary certified reference materials (CRMs) for further use in external quality assessment schemes to monitor the accuracy and comparability of the commercially available immunoassay results and to confirm the need for improving the harmonization of PCT assays. The candidate RMP will also be used to evaluate whether the correlation between the candidate RMP and immunoassays is sufficiently high. Overall, this candidate RMP will support reliable sepsis diagnosis and guide treatment decisions, patient monitoring, and outcomes.
降钙素原(PCT)是一种广泛用于快速脓毒症诊断和抗生素管理的生物标志物。商业检测中结果的变异性突出表明需要对 PCT 测量进行标准化。已经开发和验证了一种基于同位素稀释质谱和蛋白质校准方法的无抗体候选参考测量程序(RMP),用于定量人血清中的 PCT。该方法允许在 0.25 至 13.74μg/L(>0.998)的范围内定量 PCT,并在样品稀释后 PCT 浓度高于 13.74μg/L 的情况下扩展至 132μg/L。日内偏差在-3.3%至+5.7%之间,日间偏差在-3.0%至-0.7%之间。日内精密度低于 5.1%,日间精密度低于 4.0%。候选 RMP 成功应用于五个冷冻人血清池中的 PCT 绝对定量。作为主要校准品的重组 PCT 采用高分辨率质谱和氨基酸分析进行了表征,以建立结果与 SI 单位的可追溯性。该候选 RMP 适合为二级认证参考物质(CRM)赋值,以进一步用于外部质量评估计划,以监测商业免疫测定结果的准确性和可比性,并确认需要改善 PCT 测定的协调性。候选 RMP 还将用于评估候选 RMP 与免疫测定之间的相关性是否足够高。总体而言,该候选 RMP 将支持可靠的脓毒症诊断并指导治疗决策、患者监测和结果。